Topical immunomodulation. Charoen Choonhakarn,MD Division of Dermatology Khon Kaen University
|
|
- Neal Houston
- 5 years ago
- Views:
Transcription
1 Topical immunomodulation Charoen Choonhakarn,MD Division of Dermatology Khon Kaen University
2 Vitiligo
3 Atopic dermatitis
4 Seborrheic dermatitis
5 Oral lichen planus
6 Anogenital warts
7 Bowen s disease actinic keratosis
8 Malignant melanoma
9 Basal cell carcinoma
10 Side effects
11 Topical immunotherapy Immune response modifier Immunomodulator
12 Immune system -Innate immune system phagocytic cells to recognized pathogen natural killer cells (NK) -Adaptive or acquired immune system recognition of foreign Ag by major histocompatibility complex (MHC) I,II and by Agpresenting cell (Langerhans cells)
13 Topical immunomodulation Proinflammatory agents: Toll-like receptor (TLR) agonist, interferon; boost innate and acquired immune response/shifting the balance of T- helper1/t-helper2 (Th1/Th2) Immunosuppressive agents: corticosteroids, anti-tnf agents, anti- CD4+T cell agents
14 Topical immunomodulation Immune enhancers Obligate contact allergens Dinitrochlorobenzene (DNCB) Diphencyprone (DCP) Squaric acid dibutyl ester (SADBE) Toll-like receptor (TLR) agonist Imiquimod 5% Resiquimod Immunosuppressive agents Topical corticosteroids Calcineurin inhibitors: macrolactam Tacrolimus 0.03%,0.1% Pimecrolimus 1% Mycophenolate mofetil
15 Toll-receptor Toll receptor : fruit fly, Drosophila melanogaster, antifungal defense Family of type I transmembrane TLR express on APCs (macrophages, dendritic cells) : innate immune system Engagement of TLRs with their ligands elicits a pathogen-specific cellular immune response Provoke proinflammatory and antimicrobial response eg. cytokines, chemokines
16 Toll-receptor This stimulation depends on protein MyD88 MyD88+protein kinase+transcription factor activates NF-ĸB, then produces key cytokines eg. IFN-α, TNF-α, IL-1,6,12 TLRs detected in human neutrophils, macrophages, dendritic, dermal endothelial, mucosal epithelial, B and T cells Alert the immune system to the presence of a pathogen
17 CD4+ cells recognize Ag in association with MHC class II Th 1 cytokines induce cell-mediated or innate immunity (IL-2, IFN-γ, TNF-β) Th 2 cytokines induce humoral immunity (IL-4,5,6,9,10,13)
18 Toll-like receptor (TLR)
19 Toll-like receptor (TLR)
20
21 Immunosuppressive agents Cyclosporin: cyclosporin-cyclophilin complex: calcineurin inhibition blocks NF-AT binding IL-2 gene promotor: suppress T-cell activation and proliferation Tacrolimus, pimecrolimus: macrolactam isolated from Streptomyces interact with macrophilin 12 (FK binding protein)
22 Calcineurin inhibitors
23
24 Contact sensitizers DNCB, DCP and SADBE Immunotherapy of warts, alopecia areata, skin cancers Mechanism: type IV hypersensitivity Cell-mediated response acts against complex of contact agent Alter expression of anti hair follicle epitopes/antibodies for alopecia areata
25 Treatment of warts Clearance rate: 69-91% for DNCB 62-88% for DCP 11-86% for SADBE Mean duration of therapy 7 weeks S/I: eczema, blistering (56%), contact urticaria, vitiligo-like
26
27
28
29 Other indications DNCB: 80% regression of BCC and SCC and actinic keratosis from total 2000 lesions 32% complete response in 113 tumors Complete clinical response of melanomas DCP: extensive alopecia areata; regrowth of terminal hair 48% Chronic prurigo nodularis, refractory atopic dermatitis
30 Imidazoquinolines Imiquimod and resiquimod Antiviral and antitumor properties Not display direct antiviral and antiproliferative actions but through stimulation of innate immunity
31
32 Anti-virus Anti-tumor
33 Anogenital warts Several double-blind, randomized, placebo-controlled trials Largest trial: 311 male and female; 1%,5% imiquimod (apply 3 times/wk) and placebo Total clearance rate with 5% imiquimod and placebo 50% vs 11%, p< Median time for clearance 8 wk for women and 12 wk for men
34 Efficacy of topical imiquimod (IM) in adult patients with anogenital warts. Summary of randomised, double-blind trials Trial Treatment [duration /wk] No. of pts Clearance (% of pts) Complete [time to clearance (wk)] > 50% Recurrence in pts with complete clearance; no of pts (%) Sustain clearanc e rate (%) Arican et al IMI 5% 2x/wk for 8h [12] 33 70[NR] 97 0/23 (0) 70 [24] PLA [NR] 20 1/1 (100) 0 [24] Beutner et al IMI 5% 3x/wk for 24h [8] [4-10] 76 3/16 (19) 29 [10] PLA 50 0 [NA] 8 NA 0 [10] Beutner at al IMI 5% qd for 8h [<16] 94 52[med 9] 93 9/48 (19) 41 [12] IMI 1% qd for 8 h [<16] PLA [med 7] 3 [med 12] /12 (17) 0/3 (0) 11 [12] 3 [12] Edwards et al IMI 5% 3x/wk for 6-10h [<16] [8-12] 76 6/45 (13) 36 [12] IMI 1%3x/wk for 6-10h [<16] [NR] 35 0/18 (0) 21 [12] PLA [NR] 28 1/10 (10) 9 [12]
35 Efficacy of topical imiquimod (IM) in adult patients with anogenital warts. Summary of randomised, double-blind trials Trial Treatment [duration /wk] No. of pts Clearance (% of pts) Complete [time to clearance (wk)] > 50% Recurrence in pts with complete clearance; no of pts (%) Sustain clearanc e rate (%) Nakagawa IMI 5% 3x/wk for 6-10h [<16] 55 (47) 64[med 8] NR NR NR IMI 1% 3x/wk for 6-10 h [<16] 57 (44) 40 [med 8] NR NR NR PLA 53 (47) 34 [med 11] NR NR NR Versus fluorouracil (5-FU) Romero- Sanchez et al IMI 5% 3x/wk [16] 55 (100) 58 [12] NR 1/32 (3) 56 [12] 5-FU 1% 3x/wk [16] 55 (100) 36 [13] NR 0/20 (0) 36 [12]
36
37 Efficacy of topical imiquimod (IM) with anogenital warts in HIV patients Trial Treatment No. of pts Clearance (%pts) (duration,wk) Complete Partial Cusini et al IM 3/wk( 16)HIV IM 3/wk( 16)HIV Gilson et al IM 3/wk ( 16) PLA
38 Anogenital warts Clearance rate higher and/or faster in women than men Edwards et al, Nakagawa et al: efficacy independent of gender, baseline wart area, length of time wart appeared Recurrence of warts occurred over <24 wk in 0-19% (5% imiquimod) vs 0-100% (placebo) HPV type and outcome: 132 pts, HPV type by PCR; complete response 76.2% HPV-6, 66.7% HPV-11, 35% HPV-6 plus 11 and 6.3% for unclassified HPV Frequency of application: 5%imiquimod in external genitalia in men: complete clearance 3/wk (35%), 1/day (28%), 2/day (24%), 3/day (27%),P=0.88 but increase local adverse reactions
39 Imiquimod vs ablative Rx in anogenital warts Nonblind trial, 358 pts (71% men) Total clearance Recurrence (%) Sustained efficacy (%) 3 mo 6 mo ITT at 6 mo (%) 5% imiquimod /wk-8 hr-16wk (n=115) Ablative Rx+imiquimod (n=103) Ablative Rx alone (n=100)
40 Efficacy of topical imiquimod (IM) with nongenital warts resistant to previous treatment Trial Treatment No. of pts Complete Mean time (duration,wk) clearance to clearance (%pts) (wk) Grussendorf et al IM bid( 24) Hengge et al IM 5/wk( 16) 50* 30 9 Micali et al IM 5/wk ( 16) 15** 80 3 *1/3 immunocompromised pts **Subungual and periungual warts
41
42
43 Bowenoid papulosis
44 *NS Efficacy of topical imiquimod (IM) and placebo (PL) in molluscum contagiosum applied 3/week t children aged 1-9 years Trial Treatment No. of pts Complete clearance (duration,wk) (%pts) 3M study A IM( 16) * PL M study B IM( 16) * PL Theos et al IM(12) 12 33* PL 11 9
45
46
47 Miscellaneous : HSV infection Imiquimod applied 1/wk, 2/wk, 3/wk, placebo; fail to affect the primary efficacy: recurrence in a median of 54, 60, 64, 53 days over 16-wk follow-up Imiquimod 5% not effective in HSV infection
48 Miscellaneous : Keloids Imiquimod applied daily for 8 wk to prevent recurrence of excised earlobe keloids in adult pts (n=11 and 8); recurrence free 75% at 24-wk follow-up Siriraj Hospital: 35 pts, applied daily 2 wk and alternate night 8 wk: recurrent rate 2.9% pinna and 83.3% at chest and neck Imiquimod following tangential shave excision was efficacious in earlobe keloids Imiquimod could effectively prevent recurrence of excised keloids, esp. In the area that had less tension such as pinna
49 Efficacy of topical imiquimod (IM) and placebo (PL) in actinic keratosis applied 2-3/week to 25 cm 2 treatmen areas Trial Treatment No. of pts Clearance (%pts) (duration,wk) Complete >75%reduction Alomar et al IM 3/wk(4/8) ** 66** PL Jorizzo et al IM 3/wk(4/8) ** 61** PL Koman et al IM 3/wk(16) * 64* PL Lebwohl et al IM 2/wk(4/8) * 59* PL Szeimies et al IM 3/wk(16) * 72* PL *p<0.001, **p<0.0001
50
51
52
53
54 *P<0.01,**p<0.001, ***p< Efficacy of topical imiquimod (IM) and placebo (PL) in basal cell carcinoma (BCC) Trial Treatment No. of pts Histological clearance (%pts) (duration,wk) Geisse et al IM 3/wk(12) 29 52* IM 5/wk(12) 26 81*** IM qd(12) 31 87*** IM bid(12) ** PL Geisse et al IM 5/wk(6) ** IM qd(6) ** PL Schulze et al IM qd(6) 84 80** PL 82 6 Shumack et al IM 3/wk(12) 20 60** IM 5/wk(12) 23 70** IM qd(12) 21 76* PL superficial BCC nodular BCC
55
56
57 Efficacy of topical imiquimod (IM) and placebo (PL) in lentigo maligna (stage 0 melanoma) Trial Treatment No. of pts Complete clearance (duration,wk) (%pts) Fleming et al IM qd (6) 6 67 Haque et al IM qd (12) Naylor et al IM qd (12) Powell et al IM 3/wk (6) Wolf et al IM qd ( 13) 5 100
58
59
60 5% imiquimod in alopecia universalis, applied once daily for 4 months but alopecia is recurrent
61 Extramammary Paget s disease with 5% imiquimod 3/week for 5 weeks
62 Tolerability Systemic adverse reactions: headache, nausea, anorexia, fatigue, myalgia, infection, lymphadenopathy Local skin reactions: erythema, excoriation, scabbing, erosion, edema, itching, burning, vitiligo-like
63 Topical imiquimod 5% USA Europe External genital and perianal warts in pts aged 12 years Biopsy-confirmed, primary superficial BCC in immunocompetent adults with max tumor of 2 cm on trunk, neck or extremities Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratosis on face or scalp in immunocompetent adults when surgical methods are less appropriate External genital and perianal warts in adults Small superficial BCC in adults Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratosis on face or scalp in immunocompetent adults when cryotherapy or other options are less appropriate
64 Dosage and administration Indication Frequency Duration External 3/wk for 6-10 h Until clearance or Anogenital warts for max. 16 wk Superficial BCC 5/wk for 8 h 6 wk (extra 1 cm (biopsy-confirmed) around BCC) Actinic keratosis 2/wk (US) 16 wk (US) or 4 wk 3/wk (EU) for 8 h followed by 4 wk without Rx and 1 further 4wk cycle if required (EU)
65 Conclusion Topical imiquimod is an effective option for treatment anogenital warts, sbcc and actinic keratosis Overall short-term clearance rate of 40-87% with these lesions Well tolerated and mild systemic reactions Non-invasive method, easy-to-use, self treatment, tissue-sparing and alternative to ablative treatment options
66 THANK YOU
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 26 November 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 26 November 2008 ALDARA 5%, cream Box of 12 sachets of 250 mg (CIP: 349 204-4) Applicant: MEDA PHARMA imiquimod ATC
More informationAldara. Aldara (imiquimod) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.19 Subject: Aldara Page: 1 of 5 Last Review Date: March 17, 2017 Aldara Description Aldara (imiquimod)
More informationLarge majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest risk.
Basics of Skin Cancer Detection and Treatment of Non- Melanoma Skin Cancers Large majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest
More informationImmunotherapy of Warts
Immunotherapy of Warts Jacob Mashiah, MD, MHA Dermatology and Pediatric Dermatology Dana-Dowek children s hospital Sourasky Medical Center Tel-Aviv, Israel No conflict of interest to disclose Human Papillomavirus
More informationScottish Medicines Consortium
Scottish Medicines Consortium imiquimod 5% cream (Aldara) No. (385/07) Meda Pharmaceuticals Ltd 04 April 2008 The Scottish Medicines Consortium has completed its assessment of the above product and advises
More informationCLINICAL SCIENCE. doi: /S
CLINICS 2009;64(10):961-6 CLINICAL SCIENCE TREATMENT OF CUTANEOUS TUMORS WITH TOPICAL 5% IMIQUIMOD CREAM Sabrina Sisto Alessi, Jose Antonio Sanches, Walmar Roncalli de Oliveira, Maria Cristina Messina,
More informationDeveloping the next generation of dermatology products to treat serious skin diseases
Developing the next generation of dermatology products to treat serious skin diseases Tom Wiggans Chairman and Chief Executive Officer www.peplin.com Forward Looking Statements This presentation contains
More informationField vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM
Dilemmas and Challenges in Skin Cancer Therapies and Management Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM Roger I. Ceilley, M.D. Clinical Professor of Dermatology The University of Iowa
More informationTopical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary
Topical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-8 Topical Diclofenac Gel Indication
More informationProduct Information Australia APO-IMIQUIMOD CREAM. NAME OF THE MEDICINE Imiquimod. 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
APO-IMIQUIMOD CREAM NAME OF THE MEDICINE Imiquimod. Chemical Name: 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine Structural Formula: Molecular Formula: C 14 H 16 N 4 Molecular Weight: 240.3 CAS
More informationClinical characteristics
Skin Cancer Fernando Vega, MD Seattle Healing Arts Clinical characteristics Precancerous lesions Common skin cancers ACTINIC KERATOSIS Precancerous skin lesions Actinic keratoses Dysplastic melanocytic
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More information#1722. Diphencyprone for the treatment of dermatological disorders with an immunological component
#1722 Diphencyprone for the treatment of dermatological disorders with an immunological component 1 William Levis MD, 2 Karen Bulock PhD, 2 James Cardia PhD, 2 Pamela Pavco PhD, 2 Geert Cauwenbergh, Dr.
More informationImmune response to infection
Immune response to infection Dr. Sandra Nitsche (Sandra.Nitsche@rub.de ) 20.06.2018 1 Course of acute infection Typical acute infection that is cleared by an adaptive immune reaction 1. invasion of pathogen
More informationRichard Turner Consultant Dermatologist
Old Problems & New Treatments Photo Album by Administrator Richard Turner Consultant Dermatologist Plan for tonight? Refresher on SCC and solar keratosis How to distinguish the two Classic therapy than
More informationInnate Immunity and the Paradoxes of Viral Pathogens and Tissue Injury in Gene Therapy
Innate Immunity and the Paradoxes of Viral Pathogens and Tissue Injury in Gene Therapy Daniel R. Salomon, M.D. Department of Molecular and Experimental Medicine The Scripps Research Institute Tissue and
More informationDiagnosis and Management of Actinic Keratosis (AKs)
Diagnosis and Management of Actinic Keratosis (AKs) Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Assistant Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationCutaneous Immunology: Innate Immune Responses. Skin Biology Lecture Series
Cutaneous Immunology: Innate Immune Responses Skin Biology Lecture Series The Immune Response: Innate and Adaptive Components Source: Wolff, Goldsmith, Katz, Gilchrest, Paller, Leffell. Fitzpatrick s Dermatology
More informationThings that go bump: Wart & Molluscum
Things that go bump: Wart & Molluscum Raegan Hunt, MD, PhD Chief of Section, Pediatric Dermatology Texas Children s Hospital Disclosures Off label use of products may be discussed No relevant financial
More informationWhy the basics? Back to Basics HIV Dermatology Immune reconstitution Acne. The HIV infected pt who starts ARV s 12/12/2012
Why the basics? Back to Basics HIV Dermatology 2012 Toby Maurer, MD University of California, San Francisco 1) The depleted low CD4 counts 2) The repleted aging pts 3) The group who starts ARV s at high
More informationToll-like Receptors (TLRs): Biology, Pathology and Therapeutics
Toll-like Receptors (TLRs): Biology, Pathology and Therapeutics Dr Sarah Sasson SydPATH Registrar 23 rd June 2014 TLRs: Introduction Discovered in 1990s Recognise conserved structures in pathogens Rely
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abatacept for DLE, 493 for SLE, 497 Ablative therapies, localized, for cutaneous T-cell lymphoma, 502 506. See also Cutaneous T-cell lymphoma,
More informationSkin lesions The Good and the Bad. Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry
Skin lesions The Good and the Bad Dr Virginia Hubbard Ipswich Hospital NHS Trust Barts and the London School of Medicine and Dentistry Case 1 32 year old woman Australian Lesion on back New hair growing
More informationDerm quiz. Go to this link: goo.gl/forms/kchrhmtzl3vfnlv52. bit.ly/2a8asoy. Scan the QR code with your phone
Dermatology quiz Derm quiz Go to this link: goo.gl/forms/kchrhmtzl3vfnlv52 OR bit.ly/2a8asoy OR Scan the QR code with your phone Contents Childhood rashes Pigmented lesions Sun damage Pityriasis References
More informationAllergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.
Allergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 13: Mechanisms of Immunity to Viral Disease Prepared by
More informationProduct Information ALDARA TM
Product Information ALDARA TM NAME OF THE MEDICINE is 1-(2-methylpropyl)-1H-imidazo [4,5-c]quinolin-4-amine. It is an odourless, white to off-white crystalline solid. has a molecular formula of C 14 H
More informationDNA vaccine, peripheral T-cell tolerance modulation 185
Subject Index Airway hyperresponsiveness (AHR) animal models 41 43 asthma inhibition 45 overview 41 mast cell modulation of T-cells 62 64 respiratory tolerance 40, 41 Tregs inhibition role 44 respiratory
More informationIdentifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More informationDermatological Manifestations in the Elderly. Sanjay Siddha Staff Dermatologist UHN & MSH
Dermatological Manifestations in the Elderly Sanjay Siddha Staff Dermatologist UHN & MSH Disclosure No actual or potential conflicts of interest or commercial relationships to declare Objectives Recognize
More informationExtreme dermatoheliosis: How to approach the severely sun damaged patient
Extreme dermatoheliosis: How to approach the severely sun damaged patient Anokhi Jambusaria MD, MSCE Staff Dermatologist Baylor Scott and White Health Round Rock, TX I have no relevant conflicts of interest
More informationCompany Overview. Dr. Neal Walker President and CEO. September Copyright 2016 Aclaris Therapeutics. All rights reserved.
Company Overview Dr. Neal Walker President and CEO Copyright 2016 Aclaris Therapeutics. All rights reserved. A-11 Disclaimer This presentation contains forward-looking statements, including statements
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A AA. See Alopecia areata. Acrofacial vitiligo presentation of, 135, 136 AD. See Atopic dermatitis. Adaptive immunity and vitiligo, 258
More informationLumps and Bumps: An Organized Approach to Diagnosis and Management. Disclosure. Introduction. References. Structure of Skin.
Lumps and Bumps: An Organized Approach to Diagnosis and Management Nothing to disclose Disclosure Tammy Pifer Than, MS, OD, FAAO Carl Vinson VAMC tammythan@bellsouth.net References Fitzpatrick's Color
More informationAllergic rhinitis (Hay fever) Asthma Anaphylaxis Urticaria Atopic dermatitis
Hypersensitivity Disorders Hypersensitivity Disorders Immune Response IgE Disease Example Ragweed hay fever IgG Cytotoxic Immune complex T Cell Hemolytic anemia Serum sickness Poison ivy IgE-mediated Diseases
More informationProf. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology
By Prof. Ibtesam Kamel Afifi Professor of Medical Microbiology & Immunology Lecture objectives: At the end of the lecture you should be able to: Enumerate features that characterize acquired immune response
More informationCONDITIONS OF THE SKIN
CONDITIONS OF THE SKIN UCSF/SFGH Family & Community Medicine Residency Program Educational Objectives I. Knowledge The resident will be able to discuss the definition, diagnosis, and initial management
More informationCommon Benign Lesions and Skin Cancers. 22nd May 2015 Dr Mark Foley
Common Benign Lesions and Skin Cancers 22nd May 2015 Dr Mark Foley Thank you for downloading this file. This intended to supplement the presentation given at the NZ Wound Care Conference, it is not intended
More informationOpinion 26 June 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 26 June 2013 PICATO 150 µg/g, gel 3 tubes of 0.47 g (CIP: 34009 268 528-4 9) PICATO 500 µg/g, gel 2 tubes of 0.47
More informationBenign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late
More informationDESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S
Regardless of your future field of practice, you will be exposed to a considerable amount of dermatology and this rotation provides you the chance to see a range of skin diseases. You will have the opportunity
More informationLearning Objectives. Tanning. The Skin. Classic Features. Sun Reactive Skin Type Classification. Skin Cancers: Preventing, Screening and Treating
Learning Objectives Skin Cancers: Preventing, Screening and Treating Robert A. Baldor, MD, FAAFP Professor, Family Medicine & Community Health University of Massachusetts Medical School Distinguish the
More informationHPV Management in Special Populations
HPV Management in Special Populations MELISSA KOTTKE, MD, MPH, MBA Disclosures Merck, Nexplanon trainer CSL Behring, Consultant Evofem, Advisory Board Most treatment options for HPV in special populations
More informationDermatology GP Referral Guidelines
Austin Health Dermatology Department holds 5 Clinic sessions to discuss and plan the treatment of with Dermatology conditions. Department of Health clinical urgency categories for specialist clinics Urgent:
More informationWhat is atopic dermatitis?
What is atopic dermatitis? Complex inflammatory skin disorder intense pruritus cutaneous hyperreactivity immune dysregulation Chronic with exacerbations and remissions Affects all ages, but more common
More informationGeneral Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center
General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses
More informationDiagnosis and Management of the Hair Loss Patient: Pearls and Pitfalls
Diagnosis and Management of the Hair Loss Patient: Pearls and Pitfalls U033 July 30 th 2017 7:30-8:30AM Paradi Mirmirani, MD The Permanente Medical Group, Vallejo, CA Regional Director, Hair Disorders
More informationImiquimod to Treat Different Cancers of the Epidermis
COMMUNICATIONS AND BRIEF REPORTS Imiquimod to Treat Different Cancers of the Epidermis JAN EKLIND, MD, n ULRIKE TARTLER, MD, w JAN MASCHKE, MD, w PETER LIDBRINK, MD, n ULRICH R. HENGGE, MD w n Department
More informationMolluscum contagiosum (MC) is a common
THERAPEUTICS FOR THE CLINICIAN Effectiveness of Imiquimod Cream 5% for Treating Childhood Molluscum Contagiosum in a Double-blind, Randomized Pilot Trial Amy U. Theos, MD; Rebecca Cummins, MD; Nanette
More informationThe Old, The New and the Reemerging-HIV Dermatology. Toby Maurer, MD
The Old, The New and the Reemerging-HIV Dermatology Toby Maurer, MD 1 Psoriasis Widespread psoriasis, especially if it was once stable, predicts falling CD4 count?resistance to ART??Non-adherence? Tx:
More information15 Immunodeficiencies
15 Immunodeficiencies A. Acquired causes of immunodeficiencies 1. Environmental (UV irradiation) 2. Drug induced (immunosuppressants) 3. non-hiv Viral (measles virus) Dr. Andrea Hubbard School of Pharmacy
More informationInnate immunity. Abul K. Abbas University of California San Francisco. FOCiS
1 Innate immunity Abul K. Abbas University of California San Francisco FOCiS 2 Lecture outline Components of innate immunity Recognition of microbes and dead cells Toll Like Receptors NOD Like Receptors/Inflammasome
More informationImmune System. Presented by Kazzandra Anton, Rhea Chung, Lea Sado, and Raymond Tanaka
Immune System Presented by Kazzandra Anton, Rhea Chung, Lea Sado, and Raymond Tanaka Content Standards 35.1 In innate immunity, recognition and response rely on traits common to groups of pathogens 35.2
More informationClinical Policy: Benign Skin Lesion Removal Reference Number: CP.MP.HN150
Clinical Policy: Reference Number: CP.MP.HN150 Effective Date: 6/04 Last Review Date: 8/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationInnate Immunity. Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 2 August 2016
Innate Immunity Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 2 August 2016 Objectives: Explain how innate immune system recognizes foreign substances
More informationOBSERVATION. Treatment of Lentigo Maligna (Melanoma In Situ) With the Immune Response Modifier Imiquimod
OBSERVATION Treatment of Lentigo Maligna (Melanoma In Situ) With the Immune Response Modifier Imiquimod Ingrid H. Wolf, MD; Lorenzo Cerroni, MD; Kazuo Kodama, MD; Helmut Kerl, MD Background: Surgical excision
More informationMake Love Not Warts Genital Warts
Patricia Wong, MD 735 Cowper Street Palo Alto, CA 94301 650-473-3173 www.patriciawongmd.com Make Love Not Warts Genital Warts Genital warts are the most common sexually transmitted disease. The lifetime
More informationLiving Beyond Cancer Skin Cancer Detection and Prevention
Living Beyond Cancer Skin Cancer Detection and Prevention Cutaneous Skin Cancers Identification Diagnosis Treatment options Prevention What is the most common cancer in people? What is the most common
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationTCR, MHC and coreceptors
Cooperation In Immune Responses Antigen processing how peptides get into MHC Antigen processing involves the intracellular proteolytic generation of MHC binding proteins Protein antigens may be processed
More informationThe no t-so-simple cutaneous wart
Salicylic acid is a commonly used over-the-counter treatment for nongenital warts. Clearance rates of up to 75% have been reported with salicylic acid. istockphoto 10 Clinical practice guide Dermatology
More informationImiquimod Cream: A New Multipurpose Topical Therapy for Dermatology
Imiquimod Cream: A New Multipurpose Topical Therapy for Dermatology David J. Najarian, BS, and Joseph C. English III, MD Educational Objectives Review the literature on the reported uses of imiquimod in
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More informationPRODUCT MONOGRAPH APO-IMIQUIMOD. Imiquimod Cream, 5% w/w. 250 mg single-dose packet. Immune Response Modifier
PRODUCT MONOGRAPH APO-IMIQUIMOD Imiquimod Cream, 5% w/w 50 mg single-dose packet Immune Response Modifier APOTEX INC. DATE OF REVISION: 50 Signet Drive February 8, 0 Toronto, Ontario M9L T9 Control No.
More informationChapter 35 Active Reading Guide The Immune System
Name: AP Biology Mr. Croft Chapter 35 Active Reading Guide The Immune System Section 1 Phagocytosis plays an important role in the immune systems of both invertebrates and vertebrates. Review the process
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Cream 1% DK/H/PSUR/0009/005 Date of FAR:
0BCore Safety Profile Active substance: Pimecrolimus Pharmaceutical form(s)/strength: Cream 1% P-RMS: DK/H/PSUR/0009/005 Date of FAR: 06.06.2013 4.3 Contraindications Hypersensitivity to pimecrolimus,
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationI have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee
I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee Some thoughts Is this skin cancer? How common is this? How likely is this in this patient? What happens next if it s something
More informationPRODUCT INFORMATION METVIX
PRODUCT INFORMATION METVIX NAME OF THE MEDICINE Methyl aminolevulinate (as hydrochloride). Structural formula: O OCH 3 NH 3 + Cl - O CAS number: 79416-27-6 DESCRIPTION Metvix cream contains 160 mg/g of
More informationThe Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep
The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep invaders out of the body (pp. 772 773; Fig. 21.1; Table
More informationDr. Ashish Jagati, Dr. Shreya Agarwal, Dr. Kirti S Parmar, Dr. Bela J Shah, Dr. Jaydip Tank
2017; 3(2): 37-41 ISSN Print: 2394-7500 ISSN Online: 2394-5869 Impact Factor: 5.2 IJAR 2017; 3(2): 37-41 www.allresearchjournal.com Received: 09-12-2016 Accepted: 10-01-2017 Dr. Ashish Jagati Assistant
More information11/25/2017. THE IMMUNE SYSTEM Chapter 43 IMMUNITY INNATE IMMUNITY EXAMPLE IN INSECTS BARRIER DEFENSES INNATE IMMUNITY OF VERTEBRATES
THE IMMUNE SYSTEM Chapter 43 IMMUNITY INNATE IMMUNITY EXAMPLE IN INSECTS Exoskeleton made of chitin forms the first barrier to pathogens Digestive system is protected by a chitin-based barrier and lysozyme,
More informationSubject Index. Dry desquamation, see Skin reactions, radiotherapy
Subject Index Actinic keratosis disseminated disease 42 surgical excision 42 AIDS, see Kaposi s sarcoma Amifostine, skin reaction prophylaxis 111 Basal cell carcinoma, superficial X-ray therapy Bowen s
More informationONCOGENIC BALANITIS. G. Tchernev 1, J. Ananiev 2, J. C. Cardoso 3, S. Philipov 4 and U. Wollina 5
ONCOGENIC BALANITIS G. Tchernev 1, J. Ananiev 2, J. C. Cardoso 3, S. Philipov 4 and U. Wollina 5 1 Polyclinic for Dermatology and Venerology, University Hospital Lozenetz, Saint Kliment Ohridski University,
More informationSkin Malignancies. Presented by Dr. Douglas Paauw
Skin Malignancies Presented by Dr. Douglas Paauw Disclosure: Dr. Paauw has no significant financial interest in any of the products or manufacturers mentioned. How Common Is Skin Cancer? *½ of all White
More informationHPV and Genital Dermatology. Jean Anderson MD Director, Johns Hopkins HIV Women s Health Program June 2017
HPV and Genital Dermatology Jean Anderson MD Director, Johns Hopkins HIV Women s Health Program June 2017 Gilead-own stock Disclosures Objectives Describe epidemiology of genital HPV infection in the US
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationCorporate Medical Policy
Corporate Medical Policy Dermatologic Applications of Photodynamic Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: dermatologic_applications_of_photodynamic_therapy 10/2003
More informationAll animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity
1 2 3 4 5 6 7 8 9 The Immune System All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity Figure 43.2 In innate immunity, recognition and
More informationCurrent Treatment of Verruca. Mickey D. Stapp, DPM Evans, GA
Current Treatment of Verruca Mickey D. Stapp, DPM Evans, GA Etiology Infection of the epithelium with HPV Affects 7-10 percent of population Plantar verruca caused by HPV 1,2,4,60 or 63 Andrews Diseases
More information...: acrodermatitis continua
Appendix Index Index...: acrodermatitis continua 217-219 age of onset of AD 10 allergens - aeroallergens 38, 68, 69 - allergen avoidance 68 - autoallergens 30 - food allergens 38, 68 - house-dust mite
More informationKeratolytics and Other Topical Dermatological Agents
DRUG POLICY Keratolytics and Other Topical Dermatological Agents BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered.
More informationStructure and Function of Antigen Recognition Molecules
MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and
More informationGlenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine
Glenn D. Goldman, MD University of Vermont Medical Center University of Vermont College of Medicine Recognize and identify the main types of skin cancer and their precursors Identify and understand new
More informationEfficacy of Topical Diphencyprone in the Treatment of Alopecia Areata
Original Article Efficacy of Topical Diphencyprone in the Treatment of Alopecia Areata Maryam Akhiani, MD Hasan Seyrafi, MD Farshad Farnaghi, MD Parastoo Banan, MD Vahideh Lajvardi, MD Department of Dermatology,
More informationCOMMON VIRAL INFECTIONS. Dr D. Tenea Department of Dermatology University of Pretoria
COMMON VIRAL INFECTIONS Dr D. Tenea Department of Dermatology University of Pretoria GENERAL Viral infections of the skin important in immunocompromised Pts. Infection: direct inoculation ( warts ) or
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationIMO 3100, an antagonist of Toll like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients
IMO 3100, an antagonist of Toll like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a Phase 2a trial A. B. Kimball 1, J. Krueger 2, T. Sullivan
More informationConflicts of interest
Vulvar Cases 2 nd PANHELLANIC CONGRESS on Lower Genital Tract Disorders December 14-16 Grand Hyatt Athens Lynette J. Margesson MD FRCPC Assistant Professor of Obstetrics & Gynecology and Surgery(Dermatology)
More informationimmunity defenses invertebrates vertebrates chapter 48 Animal defenses --
defenses Animal defenses -- immunity chapter 48 invertebrates coelomocytes, amoebocytes, hemocytes sponges, cnidarians, etc. annelids basophilic amoebocytes, acidophilic granulocytes arthropod immune systems
More informationHarnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms
Harnessing the Immune System to Prevent Cancer: Basic Immunologic Mechanisms (the language of immunology) Barbara K. Dunn NCI/Division of Cancer Prevention October 23, 2017 Harnessing the Immune System
More informationAtopic Dermatitis and Topical Antipsoriatics
Atopic Dermatitis and Topical Antipsoriatics Goal(s): Restrict dermatological drugs only for funded OHP diagnoses. Moderate/severe psoriasis and moderate/severe atopic dermatitis treatments are funded
More informationIntegumentary System
Integumentary System Physiology of Touch Skin: our most sensitive organ Touch: first sense to develop in embryos Most important but most neglected sense How many sensory receptors do we have? (We have
More informationACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY
ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY The recognition of specific antigen by naïve T cell induces its own activation and effector phases. T helper cells recognize peptide antigens through
More informationCytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,
Cytokines http://highered.mcgraw-hill.com/sites/0072507470/student_view0/chapter22/animation the_immune_response.html Cytokines modulate the functional activities of individual cells and tissues both under
More informationTreatments used Topical including cleansers and moisturizer Oral medications:
Discipline: Dermatology Extended Topic: Acne & Rosacea : Onset: Location: Face Chest Back Menses if female: Regular Irregular PCOS Treatments used Topical including cleansers and moisturizer Oral medications:
More informationSkin disorders. Basal cell carcinoma December 2009 Anthony Ormerod, Sanjay Rajpara, and Fiona Craig ...
December 29 Anthony Ormerod, Sanjay Rajpara, and Fiona Craig.................................................. ABSTRACT INTRODUCTION: (BCC) is the most common form of skin cancer, predominantly affecting
More information生命科学基础 (21)- 动物的免疫器官. The Immune System. KE, Yuehai 柯越海. Zhejiang University, School of Basic Medical Sciences (BMS-ZJU) 浙江大学基础医学院
生命科学基础 (21)- 动物的免疫器官 The Immune System KE, Yuehai 柯越海 Zhejiang University, School of Basic Medical Sciences (BMS-ZJU) 浙江大学基础医学院 Outlines The Immune System 1. Innate immunity 2. Adaptive immunity 3. Immune
More information